Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$41.37M$41.37M+33.9% vs Q1 2023 Net Income-$136.06M-$136.06MN/M vs Q1 2023 EPS Diluted-$1.76-$1.76N/M vs Q1 2023 Operating Income-$139,237,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Free Cash Flowderived-$119,005,000N/M Margins · derivedOperating margin-336.5%−21.3 pt vs Q1 2023
Net margin-328.9%−49.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 6, 2024 · 36 d after period end